Home - Products - Metabolic Enzyme/Protease - MMP - NSC 405020

NSC 405020

CAS No. 7497-07-6

NSC 405020( NSC-405020 | NSC 405020 | NSC405020 )

Catalog No. M15856 CAS No. 7497-07-6

NSC 405020 is a noncatalytic inhibitor of MT1-MMP, directly interacts with PEX domain of MT1-MMP, affects PEX homodimerization but not catalytic activity of MT1-MMP.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
1 mL x 10 mM in DMSO	28	In Stock
5MG	37	In Stock
10MG	57	In Stock
25MG	114	In Stock
100MG	325	In Stock
200MG	491	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

NSC 405020
Note

Research use only, not for human use.
Brief Description

NSC 405020 is a noncatalytic inhibitor of MT1-MMP, directly interacts with PEX domain of MT1-MMP, affects PEX homodimerization but not catalytic activity of MT1-MMP.
Description

NSC 405020 is a noncatalytic inhibitor of MT1-MMP, directly interacts with PEX domain of MT1-MMP, affects PEX homodimerization but not catalytic activity of MT1-MMP.
In Vitro

——
In Vivo

——
Synonyms

NSC-405020 | NSC 405020 | NSC405020
Pathway

Metabolic Enzyme/Protease
Target

MMP
Recptor

MT1-MMP
Research Area

Cancer
Indication

——

Chemical Information

CAS Number

7497-07-6
Formula Weight

260.16
Molecular Formula

C12H15Cl2NO
Purity

>98% (HPLC)
Solubility

Ethanol: 52 mg/mL (199.87 mM); DMSO: 52 mg/mL (199.87 mM)
SMILES

O=C(NC(C)CCC)C1=CC=C(Cl)C(Cl)=C1
Chemical Name

3,4-Dichloro-N-(1-methylbutyl)benzamide

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1.Remacle AG, et al. Y Res. 2012 May 1;72(9):2339-49.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

CTS-1027

A potent, selective, broad-spectrum MMP inhibitor with Ki of <9 nM for MMP2, 3, 8, 9, 12, 13 and 14.
CL-82198

CL-82198 is a selective inhibitor of MMP-13 and it is a pharmacologic treatment for preventing osteoarthritis (OA) progression.
Sulfatinib

Sulfatinib may be a potent drug for cancer. It inhibits KDR and FGFR1 enzymatic activity. It also is a hERG inhibitor.

Sign In Join Free